Æterna Zentaris About
Æterna Zentaris: On
the Market Cetrotide®
was the first luteinizing hormone-releasing
hormone (LHRH) antagonist treatment approved
for in vitro fertilization. Ø Perifosine Phase 3 Multiple myeloma
and colorectal cancer Ø AEZS-108 Phase 2 Endometrial cancer
and ovarian cancer Ø AEZS-112 Phase 1 Solid tumors and lymphoma
> Endocrinology: Ø AEZS-130 Phase 3 Diagnostic test for
Adult Growth Hormone Deficiency Phase 1 Therapeutic agent in tumor induced
cachexia AEZS-120
Prostate cancer vaccine Phase 1
Key
Statistics fo Æterna
Zentaris
Æterna Zentaris Inc. operates as a late-stage
drug development company specialized in
oncology and endocrinology. Its lead oncology
compounds include perifosine, an orally
active PI3K/Akt pathway inhibitor that
is in Phase III registration trial for
multiple myeloma; and AEZS-108, a doxorubicin-targeted
conjugate in Phase II for the treatment
of advanced ovarian and endometrial cancer.
The company?s lead endocrinology compound,
AEZS-130, is an oral ghrelin antagonist
in Phase III trial as a diagnostic test
for Adult Growth Hormone Deficiency. Its
pipeline also includes earlier-stage compounds,
such as AEZS-112 that is in a Phase I
trial in advanced solid tumors and lymphoma,
as well as AEZS-120, an anti-cancer vaccine
in pre-clinical development. The company
was founded in 1991 and is headquartered
in Quebec City, Canada. (Source: Yahoo
Finance)
The
Pipeline:
More on Æterna
Zentaris:
Basic
Chart for
Æterna
Zentaris
Analyst
Opinion
Analysts
Estimates